Navigation Links
Drug shows promise for Huntington's disease
Date:2/8/2010

An early stage clinical trial of the experimental drug dimebon (latrepirdine) in people with Huntington's disease appears to be safe and may improve cognition. That is the conclusion of a study published today in the Archives of Neurology.

"This is the first clinical trial that has focused on what is perhaps the most disabling aspect of the disease," said University of Rochester Medical Center neurologist Karl Kieburtz, M.D., the lead author of the study. "While more investigation needs to be done, these results are encouraging and show, for the first time, a statistically significant benefit in terms of improved cognitive function in patients with Huntington's disease."

Huntington's disease is a progressive neurodegenerative disorder that impacts movement, behavior, cognition, and generally results in death within 20 years of the disease's onset. The disease steadily erodes a person's memory and their ability to think and learn. Over time, this cognitive impairment contributes to the loss of the ability to work and perform the activities of daily life. There are no treatments current available that effectively alter the course of the disease or improve cognition.

It is believed that mitochondria the part of the cell that helps convert food to energy plays a role in the development of Huntington's disease. Lampridine stabilizes and enhances mitochondrial function, a result that has been shown to improve behavioral, cognitive, and functional outcomes in Alzheimer's disease. Scientists speculate that this may have the same effect in patients with Huntington's disease.

The investigators studied the impact of the drug on 91 patients over a 90 day period. Half were given the drug and the other half a placebo. The patients were then evaluated using a cognitive tool called the Mini-Mental State Examination. This exam which is used by clinicians to evaluate the stage and severity of dementia and Alzheimer's disease consists of series of questions used to test an individual's orientation, memory, and ability to follow commands. The researchers found that the drug on average improved the scores of people taking the drug vs. those who received the placebo.

Dimebon is being developed by Medivation, Inc., a San Francisco-based pharmaceutical company which funded the study. The drug is also being testing in patients with Alzheimer's disease. In July of last year, Medivation and Pfizer, Inc. launched a Phase 3 clinical trial of the drug for Huntington's disease. The study, called the Horizon Trial, is being conducted in sites throughout North America, Australia, and Europe. Kieburtz is the principal investigator of the Horizon Trial.


'/>"/>

Contact: Mark Michaud
mark_michaud@urmc.rochester.edu
585-273-4790
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. New Study Shows Nearly One Third of Overweight Adolescents See Themselves as Underweight or About Right
2. Blacks with MS have more severe symptoms, decline faster than whites, new study shows
3. Herbals Not the Answer for Asthma, Study Shows
4. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
5. Experimental stem cell treatment arrests acute lung injury in mice, study shows
6. Violence is part of the job say nurses as study shows only 1 in 6 incidents are reported
7. A Study by Celibre Medical Corporation Shows Botox Injections to be the Most Desirable Cosmetic Procedure in Southern California
8. Diabetes patients rank health concerns differently than their doctors, U-M survey shows
9. Fear of Frailty: Research Shows Lack of Activity Threatens Seniors' Independence
10. New study shows effectiveness of MEND program in prevention and treatment of pediatric obesity
11. More smokers kick the habit with extended nicotine patch therapy, Penn research shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Pediatric ... to improve care by making data on heart procedures public and easily understandable ... Transparency and Public Reporting of Pediatric and Congenital Heart Disease Outcomes will bring ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a ... Dallas plastic surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore ... outlines recommendations for rhinoplasty surgeons when addressing this vital area. , The upper ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical Systems, ... with highly adaptable algorithms, has been updated to help Emergency Department physicians and ... consistent with Zikas and a travel history to affected regions, or potential exposure ...
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds ... author Ray Clarke poses a question as a challenge for his readers to ... "Being in the Being" (published by Partridge Singapore), Clarke explores the subject with ...
(Date:2/11/2016)... ... 11, 2016 , ... Life is known for throwing curves. It’s thrown quite ... gather once a year to play softball to raise money through Sun Health ... than 50 players who competed in this year’s softball tournament share a history of ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... development services for the pharmaceutical and biotechnology industries, ... in its Charleston, SC ... recent investments. Charleston ... with small-scale lyophilization. The site has invested in ...
(Date:2/11/2016)... , 11 de fevereiro de 2016  A ... sua fábrica de soroalbumina bovina (BSA -- ... fábrica fica na Ilha Norte da Nova Zelândia, ... e estabelecido na fábrica da Proliant nos EUA, ... O projeto e instalação dos equipamentos foram feitos ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
Breaking Medicine Technology: